DuPont Nutrition & Health Introduces HOWARU® Shape

Share Article

Breakthrough Probiotic Clinically Proven to Trim Your Waist

DuPont Red Oval Logo
HOWARU® Shape is geared toward those who want to lose weight but need help. We’re proud to offer these customers a proven way to manage their body shape naturally.

Today, DuPont Nutrition & Health (DuPont) announced the launch of HOWARU® Shape, an innovative probiotic formula clinically proven to reduce waist circumference in overweight adults. (Vitafoods Europe—Booth #Y143)

In a clinical study, HOWARU® Shape, which contains 10 billion CFU Bifidobacterium lactis B420™, reduced waist circumference by up to one inch. When taken in combination with 12g Litesse® Ultra™ prebiotic fiber, HOWARU® Shape also was shown to reduce body fat mass and trunk fat. The study was conducted with 225 healthy volunteers (healthy, BMI 28–34.9) who were randomized into four groups (1:1:1:1), using a computer-generated sequence, for 6 months of double-blind, parallel treatment.

Probiotic strain B420™ has been demonstrated in-vitro to increase epithelial integrity, a key function of the digestive tract. Litesse® Ultra™ prebiotic fiber has been shown in clinical studies to reduce energy intake, increase satiety and decrease after-meal feelings of hunger. Separately, and in combination, the probiotic strain B420™ and Litesse® Ultra™ demonstrate health benefits.

Clinically demonstrated benefits of HOWARU® Shape in combination with Litesse® Ultra™ versus placebo.

  •     4.5 percent reduction in total body fat mass
  •     6.7 percent reduction in trunk fat
  •     1 inch (2.6cm) reduction in waist circumference

“DuPont continues to be the leader in scientific innovation with the broadest range of clinically documented probiotics, and HOWARU® Shape is the latest breakthrough,” said Anders Gron Norager, director, Global Probiotics at DuPont. “In 2016, the global weight loss supplement market was an almost $5 billion category and growing, and we know these consumers are not just interested in dieting, they want overall health and wellness, which includes looking good. HOWARU® Shape is geared toward those who want to lose weight but need help. We’re proud to offer these customers a proven way to manage their body shape naturally.”

HOWARU® Shape does not contain stimulants and is proven safe, effective and well-tolerated. It is a highly stable product, and ideal for capsules or sachets. For more information on HOWARU® Shape, please visit danisco.com/shape.

DuPont Nutrition & Health combines in-depth knowledge of food and nutrition with current research and expert science to deliver unmatched value to the food, beverage and dietary supplement industries. We are innovative solvers, drawing on deep consumer insights and a broad product portfolio to help our customers turn challenges into high-value business opportunities. More information is available at http://www.food.dupont.com.

DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.

Forward-Looking Statements: This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company’s intellectual property rights; successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses; and risks related to the agreement entered on December 11, 2015, with The Dow Chemical Company pursuant to which the companies have agreed to effect an all-stock merger of equals, including the completion of the proposed transaction on anticipated terms and timing, the ability to fully and timely realize the expected benefits of the proposed transaction and risks related to the intended business separations contemplated to occur after the completion of the proposed transaction. The company undertakes no duty to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

# # #

5/9/17

References:

Putaala H., Salusjarvi T., Nordstrom M., Saarinen M., Ouwehand A.C., Bech Hansen E., Rautonen N. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclooxygenase expression. Res. Microbiol. 2008;159:692–698     https://doi.org/10.1016/j.resmic.2008.08.002

Olli K, Salli K, Alhoniemi E, Saarinen M, Ibarra A, Vasankari T, Rautonen N, Tiihonen K. Postprandial effects of polydextrose on satiety hormone responses and subjective feelings of appetite in obese participants. Nutrition Journal 2015; 14(1): 2. 10.1186/1475-2891-14-2

Astbury NM, Taylor MA, Macdonald IA. Polydextrose results in a dose-dependent reduction in ad libitum energy intake at a subsequent test meal. British Journal of Nutrition 2013; 110(5); 934-42. 3. https://doi.org/10.1017/S0007114512005776

Hull S, Re R, Tiihonen K, Viscione L, Wickham M. Consuming polydextrose in a mid-morning snack increases acute satiety measurements and reduces subsequent energy intake at lunch in healthy human subjects. Appetite 2012; 59(3): 706-12. https://doi.org/10.1016/j.appet.2012.08.004

Stenman, Lotta K.; Lehtinen, Markus J.; Meland, Nils, Christensen; Je rey E., Yeung, Nicolas; Saarinen, Markku T.; Courtney, Michael; Burcelin, Rémy ; Lähdeaho, Marja-Leena; Linros, Juri; Apter, Dan; Scheinin, Mika; Kloster Smerud, Hilde; Rissanen, Aila; Lahtinen, Sampo; Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adult Randomized Controlled Trial, EBioMedicine (2016; 13: 190-200), doi: 10.1016/j.ebiom.2016.10.036.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chad Coleman
DuPont
+1-913-738-3673
Email >